Practical study on the application of “BRAND” pharmaceutical care model in advanced NSCLC patients with positive driver genes

YU Jiankang; GONG Wei; SHI Jinfang; TANG Jie; GONG Yinhua

doi:10.6039/j.issn.1001-0408.2026.05.18

您当前的位置：

首页 >

文章列表页 >

Practical study on the application of “BRAND” pharmaceutical care model in advanced NSCLC patients with positive driver genes

更新时间：2026-03-10

- Practical study on the application of “BRAND” pharmaceutical care model in advanced NSCLC patients with positive driver genes
- ZHONGGUO YAOFANG Vol. 37, Issue 5, Pages: 655-659(2026)
- 作者机构：
  
  苏州大学附属第一医院药学部，江苏苏州　215000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.05.18
  CLC： R95
- Received：24 September 2025，
  
  Revised：2026-02-12，
  
  Accepted：12 February 2026，
  
  Published：15 March 2026
- 稿件说明：
移动端阅览
郁件康,龚伟,石金芳,等.“BRAND”药学服务模式用于驱动基因阳性晚期NSCLC患者的实践研究 ^Δ[J].中国药房,2026,37(05):655-659.

YU Jiankang,GONG Wei,SHI Jinfang,et al.Practical study on the application of “BRAND” pharmaceutical care model in advanced NSCLC patients with positive driver genes[J].ZHONGGUO YAOFANG,2026,37(05):655-659.
郁件康,龚伟,石金芳,等.“BRAND”药学服务模式用于驱动基因阳性晚期NSCLC患者的实践研究 ^Δ[J].中国药房,2026,37(05):655-659. DOI： 10.6039/j.issn.1001-0408.2026.05.18.

YU Jiankang,GONG Wei,SHI Jinfang,et al.Practical study on the application of “BRAND” pharmaceutical care model in advanced NSCLC patients with positive driver genes[J].ZHONGGUO YAOFANG,2026,37(05):655-659. DOI： 10.6039/j.issn.1001-0408.2026.05.18.

摘要

目的

构建针对驱动基因阳性晚期非小细胞肺癌（NSCLC）患者的“BRAND”药学服务模式，为临床开展精准化、个体化肿瘤药学服务提供理论与实践参考。

方法

根据纳排标准收集2023年1月至2024年5月在我院呼吸与危重症医学科住院的患者100例，将患者随机分为对照组和干预组，每组50例。对照组接受常规药学服务，干预组接受“BRAND”药学服务（收集患者基本信息、回顾疾病治疗相关信息、精准用药评估、明确下一步个体化药学服务方案、实施用药指导及随访管理）。每3周为1个周期，研究共持续4个周期。比较干预前后两组患者的用药依从性、生活质量、实验室检验指标、药物相关不良事件发生率和患者满意度，进行效果评价。

结果

干预12周后，与对照组比较，干预组患者的用药依从性、认知功能、社会功能、满意度均显著提高（

＜0.05），疲乏、便秘的严重程度及药物相关不良事件发生率均显著降低（

＜0.05），实验室检验指标差异无统计学意义（

＞0.05）。

结论

“BRAND”药学服务模式可有效提高驱动基因阳性晚期NSCLC患者的用药依从性、改善其生活质量，为临床药师开展标准化、高质量的药学服务提供了可行路径。

Abstract

OBJECTIVE

To establish a “BRAND” pharmaceutical care model for advanced non-small cell lung cancer （NSCLC） patients with positive driver genes， providing theoretical and practical references for the clinical implementation of precise and individualized oncology pharmaceutical care.

METHODS

One hundred patients admitted to the department of pulmonary and critical care medicine in our hospital from January 2023 to May 2024 were collected meeting the inclusion and exclusion criteria. Patients were randomly divided into control group and intervention group， with 50 patients in each group. The control group received routine pharmaceutical care， while the intervention group received pharmaceutical care under the “BRAND” model （collecting patients’ basic information， reviewing disease treatment-related information， conducting precise medication assessments， formulating individualized pharmaceutical care plans for the next steps， and implementing medication guidance and follow-up management）. The study was conducted in a 3-week cycle for a total of 4 cycles. The medication compliance， quality of life， laboratory test indicators， incidence of drug-related adverse events and satisfaction of patients in both groups were compared before and after the intervention to evaluate the effects.

RESULTS

After 12 weeks of intervention， compared with the control group， the medication compliance， cognitive function， social function and satisfaction of patients in the intervention group were improved significantly （

＜0.05）； the severity of fatigue and constipation and the incidence of drug-related adverse events were significantly reduced （

＜0.05）， and there was no statistically significant difference in laboratory test indicators （

＞0.05）.

CONCLUSIONS

The “BRAND” pharmaceutical care model can effectively improve the medication compliance of patients with advanced NSCLC with positive driver genes and improve their quality of life. This study can provide a feasible path for clinical pharmacists to carry out standardized and high-quality pharmaceutical care.

关键词

Keywords

references

BRAY F ， LAVERSANNE M ， SUNG H ， et al . Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2024 ， 74 （ 3 ）： 229 - 263 .

SMOLARZ B ， ŁUKASIEWICZ H ， SAMULAK D ， et al . Lung cancer：epidemiology，pathogenesis，treatment and molecular aspect：review of literature [J ] . Int J Mol Sci ， 2025 ， 26 （ 5 ）： 2049 .

OLIVER A L . Lung cancer：epidemiology and screening [J ] . Surg Clin North Am ， 2022 ， 102 （ 3 ）： 335 - 344 .

HE J X ， SU C X ， LIANG W H ， et al . Icotinib versus chemotherapy as adjuvant treatment for stage Ⅱ-Ⅲ A EGFR-mutant non-small-cell lung cancer （EVIDENCE）：a randomised，open-label，phase 3 trial [J ] . Lancet Respir Med ， 2021 ， 9 （ 9 ）： 1021 - 1029 .

TSUBOI M ， HERBST R S ， JOHN T ， et al . Overall survival with osimertinib in resected EGFR-mutated NSCLC [J ] . N Engl J Med ， 2023 ， 389 （ 2 ）： 137 - 147 .

VALENÇA-FEITOSA F ， CARVALHO G A C ， ALCANTARA T S ， et al . Identifying health outcomes of pharmaceutical clinical services in patients with cancer：a systematic review [J ] . Res Social Adm Pharm ， 2023 ， 19 （ 4 ）： 591 - 598 .

KUCUK E ， BAYRAKTAR-EKINCIOGLU A ， ERMAN M ， et al . Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic [J ] . J Oncol Pharm Pract ， 2020 ， 26 （ 3 ）： 595 - 602 .

郭佳琳，陈慧，王淑玲 . 我国基层医疗卫生机构药学队伍及药学服务现状研究 [J ] . 中国药学杂志， 2023 ， 58 （ 15 ）： 1422 - 1429 .

RYAN D ， MURPHY A ， STÄLLBERG B ， et al . ‘SIMPLES’：a structured primary care approach to adults with difficult asthma [J ] . Prim Care Respir J ， 2013 ， 22 （ 3 ）： 365 - 373 .

MARUPURU S ， ROETHER A ， GUIMOND A J ， et al . A systematic review of clinical outcomes from pharmacist provided medication therapy management （MTM） among patients with diabetes，hypertension，or dyslipidemia [J ] . Healthcare ， 2022 ， 10 （ 7 ）： 1207 .

刘秀兰，李娟 . 基于CICARE沟通模式咳喘药学服务门诊药患沟通流程的建立 [J ] . 医药导报， 2022 ， 41 （ 6 ）： 830 - 834 .

DE OLIVEIRA-FILHO A D ， MORISKY D E ， NEVES S J F ， et al . The 8-item Morisky medication adherence scale：validation of a Brazilian-Portuguese version in hypertensive adults [J ] . Res Social Adm Pharm ， 2014 ， 10 （ 3 ）： 554 - 561 .

杜飞，张李，陈代刚，等 . 晚期非小细胞肺癌合并慢性阻塞性肺疾病患者生活质量及预后 [J ] . 中国老年学杂志， 2021 ， 41 （ 11 ）： 2424 - 2427 .

OLIVEIRA C S ， SILVA M P ， MIRANDA Í K S P B ， et al . Impact of clinical pharmacy in oncology and hematology centers：a systematic review [J ] . J Oncol Pharm Pract ， 2021 ， 27 （ 3 ）： 679 - 692 .

MASHNI O K ， NAZER L H ， KHALIL H Z ， et al . Impact of clinical pharmacy services on patient management in the chemotherapy infusion clinics：a 5-year study at a comprehensive cancer center [J ] . J Pharm Pract ， 2022 ， 35 （ 5 ）： 686 - 690 .

SARGENT W ， WHALLEY A . Implementation and outcomes of a pharmacist-led oral chemotherapy clinic at VA Maine Healthcare System [J ] . J Oncol Pharm Pract ， 2022 ， 28 （ 8 ）： 1704 - 1708 .

ZHANG P ， LV D ， ZHAO J ， et al . Evaluation of pharmacists’ interventions on drug-related problems and drug costs in patients with cancer pain [J ] . Int J Clin Pharm ， 2021 ， 43 （ 5 ）： 1274 - 1282 .

吴玲，谭秋红，罗圣平 . 药学互联网服务功能需求的卡诺分析 [J ] . 解放军医院管理杂志， 2020 ， 27 （ 6 ）： 588 - 590 .

龚银华，虞勋，杜娆，等 . 区域药学新媒体服务体系的构建与实践 [J ] . 中南药学， 2022 ， 20 （ 1 ）： 230 - 234 .

GONG Y ， WEI W ， ZHANG W ， et al . Implementation effect of a hierarchical pharmaceutical service pattern in patients with systemic lupus erythematosus [J ] . J Int Med Res ， 2023 ， 51 （ 2 ）： 3000605231154749 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploration of the comprehensive management practice pathway for long-term prescription medications in psychiatry

Construction and effectiveness analysis of working model of cough and asthma pharmaceutical care clinic

Exploration of the role of PIVAS pharmacists in optimization of parenteral nutrition prescription systems and medication safety monitoring

Influence evaluation of pharmaceutical quality control on medication therapy management services by the ECHO model

Scoping review of pharmaceutical service provided by community pharmacists for patients with chronic diseases in China

Related Author

NIU Mengxi

LI Pengfei

WANG Xue

LIU Shanshan

CAO Yanxiang

ZHUANG Hongyan

WANG Hu

BAI Li

Related Institution

Advanced Innovation Center for Human Brain Protection， Capital Medical University

Beijing Key Laboratory of Critical Bridging Technologies for Chronic Disease Drug Development/Pharmacy Department， Beijing Anding Hospital， Capital Medical University

Dept. of Pharmacy， the First Affiliated Hospital of Anhui University of Chinese Medicine

Dept. of Nursing， the First Affiliated Hospital of Soochow University

Dept. of Pharmacy， the Second Affiliated Hospital of Hebei North University

⁰